They detailed their findings in the Journal of General Internal Medicine.
The researchers collected EMR data from Denver Health Medical Center. They pinpointed patient-specific variables strongly associated with the progression to chronic opioid therapy. They defined COT as either receiving a 90-day or more supply of oral opioids with less than a 30-day gap in supply over a 180-day period or filling 10 or more opioid prescriptions over one year.
The variables linked to progression to COT include:
• A history of substance use disorder
• Receipt in the past year of a benzodiazepine
• An opioid medication or a non-opioid analgesic
• Receipt of an opioid at hospital discharge
• High opioid requirements during hospitalization
The model correctly predicted COT in 79 percent of the patients and no COT correctly in 78 percent of the patients.
“This prediction model could be incorporated into the electronic health record and would activate when a physician orders opioid medication. It would inform the physician of their patient’s risk for developing COT and may impact their prescribing practices,” said Susan Calcaterra, a fellow in addiction medicine at the CU School of Medicine.
More articles on opioids:
Trump calls for federal opioid lawsuit against drug companies
10 Colorado EDs cut opioid use by 36% in 6 months: 5 things to know
DOJ aligns with states in opioid lawsuit, increases scrutiny on drug companies: 4 things to know
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
